Epizyme, Inc.

NasdaqGS:EPZM Stock Report

Market Cap: US$247.5m

This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

Epizyme Future Growth

Future criteria checks 2/6

Key information

15.8%

Earnings growth rate

16.6%

EPS growth rate

Biotechs earnings growth28.2%
Revenue growth rate37.6%
Future return on equityn/a
Analyst coverage

Low

Last updatedn/a

Recent future growth updates

Recent updates

Epizyme GAAP EPS of -$0.21, revenue of $27.5M

Aug 09

Epizyme Acquisition By Ipsen: CVR Value

Jul 05

Some Epizyme, Inc. (NASDAQ:EPZM) Analysts Just Made A Major Cut To Next Year's Estimates

May 16
Some Epizyme, Inc. (NASDAQ:EPZM) Analysts Just Made A Major Cut To Next Year's Estimates

Epizyme: Taking Advantage Of Recent Sell-Off

Nov 25

Health Check: How Prudently Does Epizyme (NASDAQ:EPZM) Use Debt?

Sep 14
Health Check: How Prudently Does Epizyme (NASDAQ:EPZM) Use Debt?

Industry Analysts Just Made A Sizeable Upgrade To Their Epizyme, Inc. (NASDAQ:EPZM) Revenue Forecasts

Aug 10
Industry Analysts Just Made A Sizeable Upgrade To Their Epizyme, Inc. (NASDAQ:EPZM) Revenue Forecasts

Epizyme: Potential Comeback With Tazemetostat After Initial Sales Challenge

Jun 22

Is Epizyme (NASDAQ:EPZM) Using Too Much Debt?

Jun 08
Is Epizyme (NASDAQ:EPZM) Using Too Much Debt?

Epizyme gains as peer Constellation attracts sizable premium from MorphoSys

Jun 02

Epizyme, Inc. 2021 Q1 - Results - Earnings Call Presentation

May 07

Epizyme, Inc. (NASDAQ:EPZM) Analysts Just Trimmed Their Revenue Forecasts By 41%

Feb 25
Epizyme, Inc. (NASDAQ:EPZM) Analysts Just Trimmed Their Revenue Forecasts By 41%

Is Epizyme (NASDAQ:EPZM) Using Too Much Debt?

Jan 16
Is Epizyme (NASDAQ:EPZM) Using Too Much Debt?

Epizyme says Boehringer terminates collaboration agreement

Dec 24

Would Shareholders Who Purchased Epizyme's (NASDAQ:EPZM) Stock Year Be Happy With The Share price Today?

Dec 12
Would Shareholders Who Purchased Epizyme's (NASDAQ:EPZM) Stock Year Be Happy With The Share price Today?

Epizyme Q3 2020 Earnings Preview

Nov 05

Earnings and Revenue Growth Forecasts

NasdaqGS:EPZM - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/2024136-173N/AN/A3
12/31/202380-196N/AN/A4
12/31/202249-182N/AN/A4
6/30/202253-208-209-209N/A
3/31/202238-236-211-210N/A
12/31/202137-251-227-227N/A
9/30/202134-267-229-228N/A
6/30/202133-257-229-228N/A
3/31/202122-251-250-224N/A
12/31/202016-232-257-206N/A
9/30/202012-222-239-189N/A
6/30/202014-202-235-184N/A
3/31/202017-192-200-174N/A
12/31/201924-173-148-147N/A
9/30/201929-140-135-134N/A
6/30/201923-141-132-132N/A
3/31/201930-122-123-123N/A
12/31/201822-124-122-122N/A
9/30/201812-137-130-129N/A
6/30/201812-137-133-133N/A
3/31/201810-136-119-118N/A
12/31/201710-134-121-120N/A
9/30/201710-133-112-111N/A
6/30/201717-120-98-97N/A
3/31/20178-120-105-104N/A
12/31/20168-110-97-96N/A
9/30/20168-97-97-97N/A
6/30/20162-96-80-79N/A
3/31/20162-94N/A-76N/A
12/31/20153-132N/A-73N/A
9/30/201512-125N/A-72N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: EPZM is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: EPZM is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: EPZM is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: EPZM's revenue (37.6% per year) is forecast to grow faster than the US market (7.9% per year).

High Growth Revenue: EPZM's revenue (37.6% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if EPZM's Return on Equity is forecast to be high in 3 years time

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2022/08/12 03:32
End of Day Share Price 2022/08/11 00:00
Earnings2022/06/30
Annual Earnings2021/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Epizyme, Inc. is covered by 16 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Mohit BansalCitigroup Inc
Evan SeigermanCredit Suisse
Bradley CaninoCredit Suisse